Cancer · Rare Disease · Hard-to-Treat Frontiers
Targeted / immuno / cell / gene / nucleic-acid / radiopharmaceuticals: a map of the frontier therapies attacking high-unmet-need diseases, with the global and Chinese players building them
"Cancer, rare diseases, and the conditions medicine still can't crack" is what the industry calls high unmet medical need. This page doesn't bucket by disease. It lays out ten layers across the frontier therapeutic modalities attacking those problems: precision oncology (targeted small molecules / ADCs), cancer immunotherapy (checkpoints / bispecifics), cell therapy (CAR-T), gene therapy and gene editing, nucleic-acid drugs (siRNA / ASO / mRNA), radiopharmaceuticals, then neurodegeneration (CNS) and rare-disease specialists, and finally the two foundation layers of "see it first" (diagnostics and early screening) and "sell the picks and shovels" (enabling tools / CGT manufacturing). Each layer lists the leading global and Chinese innovative-drug players, with their factual therapeutic focus and commercial moat (platform barriers, the commercial standing of approved assets, orphan-drug pricing, one-time-treatment economics, manufacturing and delivery barriers, license-out). This is a factual map of the industry. It is not medical advice, not investment advice, and contains no efficacy or return forecasts.
Precision Oncology · Targeted Small Molecules and ADCs
The workhorse of modern cancer treatment: kinase inhibitors (EGFR/ALK/BTK/CDK4-6/KRAS and others) hit driver mutations precisely, and antibody-drug conjugates (ADCs) use the antibody to deliver a chemo payload straight to the tumor. China has become a global pole in ADCs (Kelun-Biotech, RemeGen, Baili-Bio, Duality), built on platform technology and large license-out deals abroad.
Co-develops/commercializes the HER2 ADC Enhertu and TROP2 ADC Datroway with Daiichi Sankyo; its own EGFR TKI Tagrisso is the targeted backbone in lung cancer
Originator of the DXd ADC platform; inventor and co-developer/manufacturer of the HER2 ADC Enhertu and TROP2 ADC Datroway; B7-H3 and HER3 DXd ADCs in development
Acquired ADC pioneer Seagen for about $43 billion, adding the Nectin-4 ADC Padcev, CD30 ADC Adcetris, and HER2 TKI Tukysa
TROP2 ADC sacituzumab tirumotecan (sac-TMT) approved in China across multiple indications; rights outside Greater China licensed to Merck (MSD) for global Phase III
HER2 ADC disitamab vedotin (RC48) conditionally approved in China for gastric cancer and others; expanding into first-line urothelial carcinoma and other indications
c-Met ADC Emrelis granted accelerated approval in previously treated non-squamous NSCLC; holds the FRα ADC Elahere (ovarian cancer) via the ImmunoGen acquisition
EGFR×HER3 bispecific ADC BL-B01D1 in multiple Phase III trials; struck a roughly $8.4 billion licensing deal with BMS in 2023
Next-generation ADC platform company; HER2 ADC DB-1303 and other multi-target ADCs in development; multiple licensing deals with BioNTech, GSK, and others
Integrated innovative-drug leader; HER2 TKI pyrotinib approved plus HER2 ADC SHR-A1811 and several other ADC/targeted candidates in development
EGFR exon20 insertion TKI sunvozertinib (ZEGFROVY) granted FDA accelerated approval in previously treated patients; first-line NDA advancing
EGFR TKI icotinib plus ALK TKI ensartinib (Ensacove, FDA-approved for ALK+ NSCLC)
Third-generation BCR-ABL inhibitor olverembatinib approved in China for T315I-mutant CML; U.S. Phase III registration advancing
VEGFR inhibitor fruquintinib (licensed abroad to Takeda as FRUZAQLA) plus MET TKI Orpathys (partnered with AZ)
Cancer Immunotherapy · Checkpoint Inhibitors and Bispecific Antibodies
Unleash or redirect the immune system against the tumor: PD-1/PD-L1 checkpoint inhibitors (Keytruda/Opdivo) release the immune brake, while bispecific antibodies (T-cell engagers, PD-1×VEGF) grab the immune cell and the tumor at once. China's Akeso, BeiGene, Innovent, and Junshi have reached global competitiveness in this modality.
Keytruda (pembrolizumab), the PD-1 inhibitor approved across dozens of indications; subcutaneous formulation approved in 2025
Opdivo (PD-1), Yervoy (CTLA-4), Opdualag (PD-1+LAG-3 combination); subcutaneous Opdivo approved
Two approved bispecifics: cadonilimab (PD-1×CTLA-4) and ivonescimab (PD-1×VEGF); ivonescimab rights abroad licensed to Summit
Multiple myeloma bispecifics Tecvayli (BCMA×CD3) and Talvey (GPRC5D×CD3); holds the CNS drug Caplyta via the Intra-Cellular acquisition
BiTE (bispecific T-cell engager) platform pioneer: Blincyto (CD3×CD19), Imdelltra (DLL3×CD3, ES-SCLC)
Tecentriq (PD-L1, including a subcutaneous formulation); holds ADCs (Kadcyla/Polivy) and diagnostics (Foundation Medicine) via Genentech
Libtayo (PD-1) approved in advanced NSCLC, cutaneous squamous cell carcinoma, and others; fianlimab (LAG-3) combination in development
Tislelizumab (PD-1) approved in China across about ten indications, with U.S./EU registration advancing; renamed BeOne in 2025, U.S. ticker BGNE→ONC
Sintilimab (PD-1, partnered with Eli Lilly) approved in China across multiple indications; struck a global strategic oncology partnership with Pfizer
Toripalimab (PD-1) approved across multiple indications in China; Loqtorzi FDA-approved for nasopharyngeal carcinoma (a China-developed and -manufactured innovative biologic reaching abroad)
Serplulimab (PD-1) approved in the EU for small cell lung cancer; reaching abroad plus a niche-tumor foothold; a biosimilar portfolio provides cash flow
Holds development and commercialization rights to Akeso's ivonescimab (PD-1×VEGF bispecific) in the U.S./Canada/Europe/Japan, with global Phase III advancing
Cell Therapy · CAR-T / TCR-T / TIL / NK
Re-engineer a patient's own (autologous) or a donor's (allogeneic) immune cells ex vivo, then reinfuse them to attack the tumor. After Kymriah opened CAR-T, several products are now approved in blood cancers, and the field is expanding into solid tumors (CLDN18.2), autoimmune disease, and "off-the-shelf" allogeneic approaches. Manufacturing complexity and cold chain are the core barriers, and the source of pricing and capacity constraints.
Holds Yescarta/Tecartus (CD19 CAR-T) via the Kite subsidiary; acquiring Arcellx in 2026 to take full control of the BCMA CAR-T anito-cel; also has the TROP2 ADC Trodelvy
Partners with Johnson & Johnson on Carvykti (cilta-cel, BCMA CAR-T) for multiple myeloma, already commercialized in several countries; DLL3 solid-tumor CAR-T in development
Tumor-infiltrating lymphocyte (TIL) therapy Amtagvi (lifileucel) approved for previously treated advanced melanoma, with approvals in multiple regions
BCMA CAR-T zevorcabtagene autoleucel (zevor-cel) approved in China for multiple myeloma; CLDN18.2 solid-tumor CAR-T satri-cel NDA accepted with priority review by the NMPA
CD19 CAR-T relmacabtagene autoleucel (relma-cel) approved in China for several B-cell lymphomas; expanding into autoimmune disease (SLE/SSc)
Allogeneic (off-the-shelf) CAR-T developer; lead asset cema-cel (CD19, first-line consolidation in LBCL, pivotal Phase II) plus a dual-target autoimmune asset
CRISPR (chRDNA) allogeneic CAR-T; CB-010 (CD19) and CB-011 (BCMA, immune-cloaking design) in development
iPSC-derived off-the-shelf NK/T-cell therapy platform; FT819 (iPSC-CD19 CAR-T, autoimmune) and others in development
Immune cell therapy; core asset EAL (activated autologous lymphocytes, for preventing post-surgical recurrence in liver cancer, granted breakthrough therapy status) plus CAR-T in development
Gene Therapy and Gene Editing
Two routes built on one-time dosing, mainly targeting rare monogenic diseases: AAV/viral vectors "add in" a working gene, while gene editing (CRISPR/base editing/prime editing) precisely "rewrites" the disease-causing mutation. Casgevy became the first approved CRISPR therapy. Value capture sits in capsid/editor-enzyme IP, delivery and capacity barriers, and the pricing and payment innovation around a one-time treatment.
Partners with Vertex on CASGEVY (exa-cel), the first approved CRISPR/Cas9 gene-editing therapy (sickle cell disease, transfusion-dependent β-thalassemia); in vivo editing in development
Leader in in vivo CRISPR editing; nex-z (LNP delivery, in-liver TTR knockdown, ATTR amyloidosis) in Phase III; also has a hereditary angioedema asset
Base-editing leader; BEAM-302 (in vivo, alpha-1 antitrypsin deficiency) and risto-cel (sickle cell disease, ex vivo) in development
AAV gene therapy ELEVIDYS approved for Duchenne muscular dystrophy (DMD); in November 2025 the FDA updated the label after fatal liver-injury events, added a boxed warning, and restricted use to ambulatory patients. Also has an exon-skipping ASO series
AAV gene therapy pioneer; HEMGENIX (hemophilia B, commercialized by CSL Behring) approved; AMT-130 (Huntington's disease, intracranial administration) in development
Licenses out its AAV capsid platform (NAV) (Novartis's Zolgensma is built on its AAV9 technology and pays royalties) plus its own RGX-202 (DMD) and other pipeline
Rare-disease gene therapy portfolio (lentiviral ex vivo + AAV in vivo); KRESLADI granted accelerated approval for severe leukocyte adhesion deficiency (LAD-I); RP-A501 (Danon disease) in development
VYJUVEK (HSV-1 vector, topical delivery of COL7A1), the first approved redosable gene therapy, for dystrophic epidermolysis bullosa; approved in multiple regions
AAV gene therapy SGT-003 (DMD, proprietary AAV-SLB101 capsid) in Phase III; also has a cardiac pipeline
Prime-editing platform; PM359 (chronic granulomatous disease, ex vivo) with early clinical data published in NEJM (the first peer-reviewed human data for prime editing)
Pivoted from 2025 to purely in vivo editing, focused on EDIT-401 (one-time cholesterol lowering, heterozygous familial hypercholesterolemia)
AAV gene therapy; BBM-H901 (China's first approved hemophilia B gene therapy, commercialized by Takeda China)
Nucleic-Acid Drugs · RNA Therapeutics (siRNA / ASO / mRNA)
Act directly on RNA rather than protein: siRNA silences a disease-causing gene, antisense oligonucleotides (ASOs) modulate splicing, and mRNA encodes a therapeutic protein or vaccine. GalNAc liver-targeted delivery has carried siRNA into large chronic-disease indications, while orphan diseases and "undruggable" targets are the main battleground. Value capture sits in the delivery platform and chemistry IP, and in platform-style license-out.
The deepest in RNAi/siRNA commercialization, with five approvals (Amvuttra/Onpattro, Givlaari, Oxlumo, plus Leqvio partnered with Novartis); first full-year profit in 2025
Founding force in the antisense oligonucleotide (ASO) platform; approvals include Spinraza (SMA, licensed to Biogen), Wainua (ATTR, with AZ), Tryngolza (FCS), and Dawnzera
mRNA platform company, with three approvals (Spikevax, mNEXSPIKE, mRESVIA); pipeline spans influenza, individualized cancer neoantigens, and rare disease
mRNA platform; beyond the COVID vaccine (Comirnaty, partnered with Pfizer) the focus has shifted to oncology: individualized neoantigen BNT122 (partnered with Roche) plus several bispecifics/ADCs; acquired CureVac to strengthen mRNA oncology
RNAi company; first approved siRNA of its own, plozasiran (familial chylomicronemia syndrome, approved by the FDA and China's NMPA); SHTG and other Phase III trials advancing
China's earliest small-nucleic-acid/siRNA drugmaker (founded 2007), listed in Hong Kong in January 2026; core pipeline RBD4059 (FXI antithrombotic), hepatitis B, and 20+ programs
Three-modality platform (ASO/siRNA/RNA editing AIMer); WVE-006 (GalNAc RNA editing, AATD), WVE-007 (obesity), and WVE-003 (Huntington's, allele-selective) in development
RNAi therapeutics (oncology/fibrosis/aesthetics); STP705 (dual-target, late-stage cutaneous squamous cell carcinoma) and STP707 (intravenous, solid tumors) in development
Integrated drugmaker centered on cardiovascular, with small nucleic acids as incremental pipeline: in-licensed AGT-siRNA (primary hypertension) and an in-house PCSK9 multi-modality effort
Started in antivirals, with small nucleic acids as incremental license-out: a 2026 global license to GSK for two siRNAs
siRNA (cardiovascular, including extrahepatic delivery); two rounds of siRNA licensing with Novartis (potential total of about $9.4 billion)
Radiopharmaceuticals · Radioligand Therapy (RLT)
Use a ligand to deliver a therapeutic isotope (Lu-177, Ac-225, and others) to the tumor, releasing radiation inside the lesion: a fast-rising new oncology modality. Short isotope half-lives force production close to the patient, making localized manufacturing and cold-chain logistics an extremely high barrier; the scarcity of medical isotopes is the upstream chokepoint. Large pharma has been buying its way in heavily in recent years.
Global RLT commercialization leader, with two approvals: Pluvicto (Lu-177 PSMA, prostate cancer) and Lutathera (Lu-177 SSTR, neuroendocrine tumors); multiple Phase III trials advancing. Also holds the CAR-T Kymriah and CDK4/6 Kisqali
Leader in U.S. PSMA PET diagnostic imaging (Pylarify); extending into therapy via M&A (a Lu-177 Dotatate radio-equivalent drug, Alzheimer's imaging)
Yttrium-90 (90Y) resin microspheres (SIR-Spheres) for selective internal radiation therapy (SIRT); the only FDA-approved product with dual indications in liver cancer and colorectal liver metastases; 12 RDCs in development, in-licensed ITM-11
Theranostic radiopharmaceutical company; lead products Illuccix/Gozellix (PSMA PET imaging); Pixclara (glioma) and Zircaix (kidney cancer) diagnostics in development
China's nuclear medicine leader; radiopharmaceutical business includes 18F-FDG, 99mTc-MDP, and others; subsidiary Atom HighTech is building out PET radiopharmaceuticals
Part of the CNNC group; business spans radiopharmaceuticals, radiation sources, irradiation, and nuclear medical equipment; marketed radiopharmaceuticals include 131I, 18F-FDG, 99mTc, 89Sr, and 125I seeds
Nuclear-engineering group whose subsidiary BWXT Medical contract-manufactures radiopharmaceuticals/medical isotopes; signed an Ac-225 supply agreement with NorthStar
Alpha-isotope Pb-212 platform radiopharmaceutical developer (clinical stage); VMT-α-NET (SSTR2, neuroendocrine tumors), VMT01 (melanoma), and others in development
Supplier of therapeutic radioisotopes, providing Ac-225 and no-carrier-added Lu-177 to multiple RLT biotechs; GMP production lines continually expanding
Chinese innovative-radiopharmaceutical company; a 15-asset pipeline including 4 core assets, with one diagnostic radiopharmaceutical commercialized; filed with the Hong Kong exchange in May 2025
Neurodegeneration and Central Nervous System (CNS)
Alzheimer's, Parkinson's, ALS, Huntington's: medicine's hardest "unsolvable" frontier. The historical failure rate here is extremely high, so the few approved assets carry a scarce commercial standing. Anti-amyloid antibodies, ASOs, and neuropsychiatric drugs make up the current mainstay. (This layer states only approved/pipeline facts and commercial moats; it does not adjudicate efficacy disputes.)
Kisunla (donanemab), an anti-amyloid antibody approved for early symptomatic Alzheimer's (approved in China, Japan, the UK, and others)
Partners with Eisai on Leqembi (lecanemab, early Alzheimer's, approved in 50+ countries); Qalsody (SOD1-ALS, ASO, licensed from Ionis); Spinraza (SMA)
Lead developer/registrant for Leqembi (lecanemab) globally, co-commercialized with Biogen; subcutaneous formulation advancing
Ingrezza (VMAT2 inhibitor, tardive dyskinesia), Crenessity; M4 agonist (schizophrenia, Phase III), depression, and others in development
Veteran CNS player: Vimpat/Briviact (epilepsy), Fintepla (rare epilepsy); acquired Neurona to move into cell therapy for epilepsy
Nuplazid (Parkinson's disease psychosis, the only approved drug in that indication), Daybue (Rett syndrome)
CNS specialty commercial platform with 9 marketed products (Qelbree for ADHD, a Parkinson's series, Zurzuvae for postpartum depression, acquired from Sage)
Psychiatry/neurology as one main line; Class 1 new drug dexmecamylamine (insomnia) approved and added to the reimbursement list; in-licensed P2B001 (Parkinson's) China rights
Dual focus on anesthesia/analgesia and CNS; CNS covers antipsychotics, antidepressants, and Parkinson's, with several Class 1 innovative drugs in development
Blood-brain-barrier TransportVehicle delivery platform; first marketed drug is for Hunter syndrome, with CNS programs spanning tau, LRRK2, and PGRN in development
Focused on prasinezumab (anti-alpha-synuclein, Parkinson's, Phase III with Roche); pipeline narrowed after restructuring
Rare-Disease Specialty · Orphan-Drug Platforms
Specialty drugmakers whose main business is rare/orphan diseases: cystic fibrosis, enzyme replacement (lysosomal storage disorders), FcRn autoimmune disease, rare kidney/liver disease. The business model is a narrow patient pool × very high pricing × long-term dosing + regulatory exclusivity + a diagnostic-identification network that locks in share. Many of the benchmarks (Alexion, Apellis) have already been acquired by large pharma.
Global leader in cystic fibrosis (CF) (flagship Trikafta/Kaftrio, next-generation ALYFTREK); expanding via Casgevy (partnered with CRISPR) and the non-opioid analgesic JOURNAVX
Leader in FcRn antibody therapy; flagship Vyvgart (efgartigimod) approved for generalized myasthenia gravis, CIDP, and other autoimmune rare diseases
Rare-lung-disease specialist; ARIKAYCE (refractory MAC lung disease) plus BRINSUPRI (brensocatib) approved as a treatment for non-cystic-fibrosis bronchiectasis
European orphan-drug specialty leader; focused on hematology (hemophilia Elocta/Alprolix), immunology (ITP, HLH, inflammation), plus royalties on the RSV prophylactic Beyfortus
Enzyme-replacement (ERT) and rare-genetic-disease platform; VOXZOGO (the only approved drug for achondroplasia) plus several lysosomal storage disorder ERTs; planning to acquire Amicus
Japan's largest drugmaker; after acquiring Shire, rare disease and plasma-derived products became a core pillar (hemophilia, inherited metabolic disease, immunology)
Ultra-rare disease specialist; 4 marketed products including Crysvita (X-linked hypophosphatemia) and Dojolvi; several AAV gene therapies in development
Rare-kidney-disease specialist; FILSPARI (sparsentan) approved for IgA nephropathy and also approved for focal segmental glomerulosclerosis (the first approved drug in that indication)
Rare cholestatic-liver-disease specialist; LIVMARLI (IBAT inhibitor, Alagille syndrome/PFIC), CHOLBAM, CTEXLI
Chinese rare-disease/rare-tumor biotech; commercialized products include Hunterase (Hunter syndrome ERT), Guirunning (Gaucher disease), and NERLYNX
Chinese inherited-rare-disease platform biotech; commercialized Agamree (vamorolone, DMD, approved in China)
Diagnostics · Early Screening · Liquid Biopsy · MRD
The prerequisite for cracking hard-to-treat disease is to "see it first": multi-cancer early detection (MCED), ctDNA liquid biopsy, minimal residual disease (MRD) monitoring, and companion diagnostics (CDx) that guide therapy. The moat sits in clinical evidence and guideline inclusion, reimbursement, lab-network scale, and companion-diagnostic ties to drugmakers.
Colorectal cancer stool-DNA early screening Cologuard / next-generation Cologuard Plus; multi-cancer early detection blood test Cancerguard; Oncotype DX for breast cancer recurrence risk
Tumor MRD/recurrence monitoring Signatera (personalized tumor-informed ctDNA); also prenatal screening Panorama and transplant-rejection monitoring
ctDNA liquid biopsy plus companion diagnostic Guardant360 / MRD monitoring Reveal; Shield blood test FDA-approved as a first-line colorectal cancer screen
Oncology/hereditary genetic testing plus a multimodal clinical-data platform (genetic diagnostics plus data licensing to drugmakers); moving into MRD monitoring
Multi-cancer early detection (MCED) blood test Galleri, screening for multiple cancers from a single blood draw; spun off from Illumina to list independently in 2024
Molecular-diagnostic sample prep and detection tools plus the companion-diagnostic therascreen series (paired CDx for several FDA-approved therapies)
clonoSEQ, the first/only FDA-approved (IVD) MRD test for blood cancers (multiple myeloma/B-ALL/CLL); distributed in partnership with Illumina
Oncology precision-medicine molecular-diagnostic reagents (PCR/NGS/IHC/FISH), spanning companion diagnostics from targeted to immuno; CDx partnerships with multinational drugmakers
Genomic diagnostics: prostate cancer Decipher (recurrence-risk stratification) and thyroid nodule Afirma (benign-vs-malignant discrimination)
Hereditary cancer genetic testing (myRisk) plus companion diagnostics plus prenatal/psychiatric pharmacogenomics
Cancer treatment-selection (CDx) genetic testing; three segments of central lab, in-hospital, and pharma R&D services (note: exposed to China-concept HFCAA audit risk)
Noninvasive prenatal testing (NIPT) plus multi-omics testing services for infectious disease, oncology, and more; a large reproductive-health/gene-sequencing platform
Enabling Tools and CGT Manufacturing · Delivery
The picks-and-shovels base that lets frontier therapies reach patients: sequencers (to read the genes), LNP/AAV delivery (to get the drug into the cell), viral-vector and cell/gene-therapy (CGT) CDMOs, and bioprocess consumables. CGT manufacturing capacity is scarce and plant build-out takes years, making it the tightest chokepoint; genuinely pure-play listed names are in fact few (most are acquired or private).
Global leader in short-read gene sequencing (NovaSeq X platform), supporting diagnostics, companion diagnostics, and CGT workflows; spun off GRAIL in 2024
One of the world's largest biologics CDMOs, spanning large molecules, drug product, bioconjugation (ADCs), and cell and gene therapy; serves 160+ CGT customers
Global leader in bioprocess equipment and single-use consumables; focuses on viral/plasmid/mRNA purification via BIA Separations; offers an integrated autologous cell-therapy platform
Viral-vector specialist CDMO focused on CGT, offering lentiviral (LVV) and AAV vector development and GMP manufacturing; a years-long supplier to BMS
Core bioprocess upstream consumables/systems (Protein A affinity ligands and resins, TFF filtration, chromatography systems); offers an AAV-dedicated chromatography resin
Life-science reagents and analytical instruments; R&D Systems supplies the GMP-grade cytokines/growth factors critical to CGT manufacturing; Simple Western protein analysis
Its ProBio unit is a large-molecule/CGT CDMO covering full CMC from IND to commercialization for plasmids, viral vectors, mRNA, and nucleic-acid drugs
China's leading domestic-substitution sequencer maker (DNBSEQ technology); broke into overseas markets after settling its global patent litigation with Illumina in 2022
Its own LUNAR lipid nanoparticle (LNP) plus STARR self-amplifying mRNA (sa-mRNA) platform; KOSTAIVE is an approved, commercialized sa-mRNA vaccine (partnered with CSL)
Long-read (HiFi/SMRT) sequencing leader, with the Revio platform and the benchtop Vega
Holds foundational LNP-delivery patents; with the private Genevant it asserts patent rights against mRNA vaccine makers (reached a large settlement with Moderna in 2026)
Key mRNA LNP delivery supplier whose clinically validated LNP is used in the Pfizer-BioNTech COMIRNATY COVID vaccine; signed a license agreement with Pfizer
Integrated CGT manufacturing-tools giant: CliniMACS Prodigy (a magnetic cell-sorting, culture, and transduction closed system), lentiviral vectors, plus its own CGT CDMO